[8-K] Aquestive Therapeutics, Inc. Reports Material Event
Aquestive Therapeutics announced a press release reporting its reported financial results for the second quarter ended June 30, 2025 and provided a business update. The press release and accompanying financial schedules are included as Exhibit 99.1 and are referenced in Item 2.02 of the Current Report.
The company also furnished investor presentations and a corporate presentation as Exhibits 99.2 and 99.3, stating those materials are available on the Events and Presentations page of its website. The filing clarifies that the disclosed materials are furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act.
Aquestive Therapeutics ha pubblicato un comunicato stampa che riporta i risultati finanziari per il secondo trimestre chiuso il June 30, 2025 e ha fornito un aggiornamento aziendale. Il comunicato e i prospetti finanziari allegati sono inclusi come Exhibit 99.1 e sono richiamati nell'Elemento 2.02 del Current Report.
L'azienda ha inoltre reso disponibili presentazioni per investitori e una presentazione aziendale come Exhibits 99.2 and 99.3, indicando che tali materiali sono consultabili nella pagina Eventi e Presentazioni del suo sito web. Il deposito chiarisce che i materiali divulgati sono forniti e non devono essere considerati 'filed' ai fini della Sezione 18 del Exchange Act.
Aquestive Therapeutics anunci贸 un comunicado de prensa con sus resultados financieros del segundo trimestre finalizado el June 30, 2025 y ofreci贸 una actualizaci贸n sobre el negocio. El comunicado y los estados financieros adjuntos se incluyen como Exhibit 99.1 y se citan en el Punto 2.02 del Current Report.
La compa帽铆a tambi茅n facilit贸 presentaciones para inversores y una presentaci贸n corporativa como Exhibits 99.2 and 99.3, indicando que esos materiales est谩n disponibles en la secci贸n Eventos y Presentaciones de su sitio web. El documento aclara que los materiales divulgados son suministrados y no deben considerarse 'filed' a los efectos de la Secci贸n 18 del Exchange Act.
Aquestive Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 瓿店皽頃橁碃 靷梾 順勴櫓鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 氤措弰鞛愲鞕� 觳秬 鞛鞛愲電� Exhibit 99.1搿� 韽暔霅橃柎 鞛堨溂氅� Current Report鞚� 頃 2.02鞐愳劀 彀胳“霅╇媹雼�.
須岇偓電� 霕愴暅 韴瀽鞛愳毄 頂勲爤鞝犿厡鞚挫厴瓿� 旮办梾 頂勲爤鞝犿厡鞚挫厴鞚� Exhibits 99.2 and 99.3鞙茧 鞝滉车頄堨溂氅�, 頃措嫻 鞛愲霌れ澊 鞛愳偓 鞗轨偓鞚错姼鞚� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴 韼橃澊歆�鞐愳劀 頇曥澑頃� 靾� 鞛堧嫟瓿� 氚濏様鞀惦媹雼�. 鞚� 鞁犼碃靹滊姅 瓿店皽霅� 鞛愲霌れ澊 鞝滉车霅�(蹿耻谤苍颈蝉丑别诲) 瓴冹溂搿滌劀 Exchange Act鞚� Section 18 氇╈爜靸� 'filed'搿� 臧勳＜霅橃柎靹滊姅 鞎� 霅滊嫟瓿� 氇呾嫓頃╇媹雼�.
Aquestive Therapeutics a publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le deuxi猫me trimestre clos le June 30, 2025 et a fourni une mise 脿 jour sur ses activit茅s. Le communiqu茅 et les tableaux financiers annexes sont inclus en tant que Exhibit 99.1 et sont mentionn茅s 脿 l'article 2.02 du Current Report.
La soci茅t茅 a 茅galement transmis des pr茅sentations aux investisseurs et une pr茅sentation corporate en tant que Exhibits 99.2 and 99.3, indiquant que ces documents sont disponibles sur la page 脡v茅nements et Pr茅sentations de son site web. Le d茅p么t pr茅cise que les documents divulgu茅s sont remis et ne doivent pas 锚tre consid茅r茅s comme 'filed' au sens de la Section 18 du Exchange Act.
Aquestive Therapeutics gab eine Pressemitteilung bekannt, in der die gemeldeten Finanzergebnisse f眉r das am June 30, 2025 beendete zweite Quartal dargestellt werden, und gab ein Gesch盲fts-Update. Die Pressemitteilung und die beigef眉gten Finanzunterlagen sind als Exhibit 99.1 enthalten und werden in Punkt 2.02 des Current Report genannt.
Das Unternehmen hat au脽erdem Investorenpr盲sentationen und eine Unternehmenspr盲sentation als Exhibits 99.2 and 99.3 bereitgestellt und erkl盲rt, dass diese Unterlagen auf der Seite Events and Presentations seiner Website verf眉gbar sind. Die Meldung stellt klar, dass die offengelegten Materialien bereitgestellt wurden und nicht als 'filed' im Sinne von Abschnitt 18 des Exchange Act zu betrachten sind.
- None.
- None.
Insights
TL;DR: Routine earnings disclosure and investor materials were furnished; the 8-K contains no numerical results within the filing text itself.
The filing serves to furnish a press release reporting the company's financial results for the quarter ended June 30, 2025, and to provide investor presentation materials. This is a standard disclosure step to make earnings and supplemental slides available to investors and analysts. The 8-K notes the materials are furnished, not filed, limiting certain legal liabilities. Investors will need to review Exhibit 99.1 and the supplemental materials for actual financial metrics because the 8-K text does not include numerical results or schedules in-line.
TL;DR: Disclosure is procedural and transparent; designation of materials as "furnished" follows common SEC practice.
The company furnished its earnings press release and investor presentations as exhibits, and explicitly stated those exhibits are not "filed" under the Exchange Act for Section 18 liability. This distinction is customary and indicates the company is providing information under Regulation FD and Form 8-K requirements. The filing also confirms presentation availability on the company website, subject to discontinuation at the company's discretion. No governance or control changes are disclosed here.
Aquestive Therapeutics ha pubblicato un comunicato stampa che riporta i risultati finanziari per il secondo trimestre chiuso il June 30, 2025 e ha fornito un aggiornamento aziendale. Il comunicato e i prospetti finanziari allegati sono inclusi come Exhibit 99.1 e sono richiamati nell'Elemento 2.02 del Current Report.
L'azienda ha inoltre reso disponibili presentazioni per investitori e una presentazione aziendale come Exhibits 99.2 and 99.3, indicando che tali materiali sono consultabili nella pagina Eventi e Presentazioni del suo sito web. Il deposito chiarisce che i materiali divulgati sono forniti e non devono essere considerati 'filed' ai fini della Sezione 18 del Exchange Act.
Aquestive Therapeutics anunci贸 un comunicado de prensa con sus resultados financieros del segundo trimestre finalizado el June 30, 2025 y ofreci贸 una actualizaci贸n sobre el negocio. El comunicado y los estados financieros adjuntos se incluyen como Exhibit 99.1 y se citan en el Punto 2.02 del Current Report.
La compa帽铆a tambi茅n facilit贸 presentaciones para inversores y una presentaci贸n corporativa como Exhibits 99.2 and 99.3, indicando que esos materiales est谩n disponibles en la secci贸n Eventos y Presentaciones de su sitio web. El documento aclara que los materiales divulgados son suministrados y no deben considerarse 'filed' a los efectos de la Secci贸n 18 del Exchange Act.
Aquestive Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 瓿店皽頃橁碃 靷梾 順勴櫓鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 氤措弰鞛愲鞕� 觳秬 鞛鞛愲電� Exhibit 99.1搿� 韽暔霅橃柎 鞛堨溂氅� Current Report鞚� 頃 2.02鞐愳劀 彀胳“霅╇媹雼�.
須岇偓電� 霕愴暅 韴瀽鞛愳毄 頂勲爤鞝犿厡鞚挫厴瓿� 旮办梾 頂勲爤鞝犿厡鞚挫厴鞚� Exhibits 99.2 and 99.3鞙茧 鞝滉车頄堨溂氅�, 頃措嫻 鞛愲霌れ澊 鞛愳偓 鞗轨偓鞚错姼鞚� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴 韼橃澊歆�鞐愳劀 頇曥澑頃� 靾� 鞛堧嫟瓿� 氚濏様鞀惦媹雼�. 鞚� 鞁犼碃靹滊姅 瓿店皽霅� 鞛愲霌れ澊 鞝滉车霅�(蹿耻谤苍颈蝉丑别诲) 瓴冹溂搿滌劀 Exchange Act鞚� Section 18 氇╈爜靸� 'filed'搿� 臧勳＜霅橃柎靹滊姅 鞎� 霅滊嫟瓿� 氇呾嫓頃╇媹雼�.
Aquestive Therapeutics a publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le deuxi猫me trimestre clos le June 30, 2025 et a fourni une mise 脿 jour sur ses activit茅s. Le communiqu茅 et les tableaux financiers annexes sont inclus en tant que Exhibit 99.1 et sont mentionn茅s 脿 l'article 2.02 du Current Report.
La soci茅t茅 a 茅galement transmis des pr茅sentations aux investisseurs et une pr茅sentation corporate en tant que Exhibits 99.2 and 99.3, indiquant que ces documents sont disponibles sur la page 脡v茅nements et Pr茅sentations de son site web. Le d茅p么t pr茅cise que les documents divulgu茅s sont remis et ne doivent pas 锚tre consid茅r茅s comme 'filed' au sens de la Section 18 du Exchange Act.
Aquestive Therapeutics gab eine Pressemitteilung bekannt, in der die gemeldeten Finanzergebnisse f眉r das am June 30, 2025 beendete zweite Quartal dargestellt werden, und gab ein Gesch盲fts-Update. Die Pressemitteilung und die beigef眉gten Finanzunterlagen sind als Exhibit 99.1 enthalten und werden in Punkt 2.02 des Current Report genannt.
Das Unternehmen hat au脽erdem Investorenpr盲sentationen und eine Unternehmenspr盲sentation als Exhibits 99.2 and 99.3 bereitgestellt und erkl盲rt, dass diese Unterlagen auf der Seite Events and Presentations seiner Website verf眉gbar sind. Die Meldung stellt klar, dass die offengelegten Materialien bereitgestellt wurden und nicht als 'filed' im Sinne von Abschnitt 18 des Exchange Act zu betrachten sind.
